Policy & Regulation
Bayer reports positive Phase III FIND-CKD results for Kerendia in non-diabetic chronic kidney disease
5 June 2026 - German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) on Friday reported full results from the Phase III FIND-CKD trial evaluating Kerendia (finerenone) in adul...
Owkin to build AI agents as part of K Pro collaboration with Sanofi
5 June 2026 - Agentic AI company Owkin announced on Friday that it has entered into a multi-year collaboration with French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) to co-develo...
Gilead and Lakefront complete Ouro Medicines acquisition to expand autoimmune disease pipeline
5 June 2026 - Biopharmaceutical company Gilead Sciences Inc (Nasdaq: GILD) and biotechnology company Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT), formerly known as Galapagos, confirmed ...
Kexing Biopharm begins enrolment for Phase I trial of GB10 in China
5 June 2026 - Chinese biopharmaceutical company Kexing Biopharm Co Ltd (SHA:688136) announced on Thursday that the first subject has been enrolled and dosed in the Phase I clinical trial in China for ...
Lupeng Pharmaceutical's rocbrutinib receives Chinese approval to treat R/R mantle cell lymphoma
5 June 2026 - Chinese clinical-stage company Lupeng Pharmaceutical Ltd announced on Thursday that China's National Medical Products Administration (NMPA) has granted accelerated approval to rocbr...
Pharming secures FDA acceptance of Joenja filing for children with APDS
4 June 2026 - Biopharmaceutical company Pharming Group N.V. (Euronext Amsterdam:PHARM) (NASDAQ:PHAR) announced on Thursday that the US Food and Drug Administration (FDA) has accepted the resubmitted s...